LDLR and familial hyperaldosteronism: Several trials of this program have already reported efficacy (with a mean of LDL-C reduction up to 57%), safety, and durable effects in different populations [14,60,61], even patients affected by LDL receptor abnormalities such as homozygous or heterozygous Familial Hypercholesterolemia (FH) [62,63].